| P/E (FY) | — | Sales (TTM) | DKK 40.3M |
| Earnings (TTM) | -DKK 82.1M | ROE | −125.60% |
| Net Margin | −203.83% | ROIC | −592.95% |
| Debt / Equity | 0.05 | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 11.62% |
BioPorto is an in-vitro diagnostics company developing biomarker tests to help clinicians detect kidney injury in critically ill patients earlier, serving Denmark, the rest of Europe, North America, and Asia. Its products include the ProNephro AKI (NGAL) pediatric test and the NGAL Test immunoassay for acute kidney injury, alongside antibodies, ready-to-use ELISA kits, and a generic rapid assay device for custom lateral-flow tests. The company is based in Hellerup, Denmark.
| Market Cap | $67,548 | Trading Days | 4010 |
| 52W High | 1.49 |
| 52W Low | 0.84 |
| % Off High | −21.37% |
| YTD | 14.71% | 1Y | −14.35% |
| 3Y | −4.88% | 5Y | −56.88% |
| 10Y | −33.91% | Since incept. (ann.) | −7.11% |
| Ann. Volatility (1Y) | 51.34% | Ann. Volatility (3Y) | 56.93% |
| Sharpe (1Y) | −0.06 | Sharpe (3Y) | 0.26 |
| Max Drawdown (1Y) | −41.31% | Max Drawdown (3Y) | −71.53% |
| Beta (3Y, vs SPY) | 0.86 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| RGBP | Regen BioPharma Inc | $51,196 | — |
| ENDV | ENDONOVO THERAPEUTICS, INC. | $31,875 | — |
| LIPO | LIPELLA PHARMACEUTICALS INC. | $151,101 | — |
| MEHA | Functional Brands Inc. | $366,020 | 0.4 |
| LIFE.OL | Lifecare ASA | $378,977 | — |
| AYRWF | Ayr Wellness Inc. | $402,411 | — |
| SSKN | STRATA Skin Sciences, Inc. | $529,938 | — |
| CERO | CERO THERAPEUTICS HOLDINGS, INC. | $559,394 | — |
| ODYY | Odyssey Health, Inc. | $605,812 | — |
| RBOT | Vicarious Surgical Inc. | $613,065 | — |
| RAY-B.ST | RaySearch Laboratories AB (publ) |
| $614,001 |
| 29.3 |
| IMCC | IM Cannabis Corp. | $641,356 | — |
